Maryland Stem Cell Research Commission Announces $4 Million in Grants to Drive Stem Cell Innovations

by secretome | Sep 20, 2023 | Investors, News

12 outstanding scientists hailing from Maryland-based research institutions and companies have been selected as recipients of these prestigious grants. Among the distinguished awardees are researchers from esteemed academic institutions, such as Johns Hopkins...

Secretome Therapeutics Appoints Margot Connor as Board Director and Assembles World-Class Clinical Advisory Board

by secretome | Jul 18, 2023 | Investors, News

DALLAS, TX, July 18, 2023 — Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells (nMSC) today announced the appointment of Margot Connor to its Board of Directors. “I have been fortunate to be part...

Secretome Therapeutics Appoints Deepa Prasad as Chief Financial Officer

by secretome | Jun 26, 2023 | Investors, News

DALLAS, TX,  June 26, 2023 — Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells (nMSC) today announced the appointment of Margot Connor to its Board of Directors. “I have been fortunate to be...

Neoprogen is now Secretome Therapeutics, in alignment with the company’s focus in revolutionizing cell therapy via neonatal cardiac progenitor cells (nCPCs) and their respective secretomes 

by secretome | Jun 1, 2023 | Investors, News, Uncategorized

NeoProgen receives approval from U.S. FDA for a Phase I Study of The Safety And Early Efficacy of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) In Chronic Ischemic Heart Failure

by secretome | May 23, 2023 | Investors, News

BALTIMORE, MD., June 10, 2021 — NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and other...

NeoProgen, Inc. Receives First Granted Patent for Method to Treat Cardiac Conditions using Neonatal Heart-derived Medicinal Signaling Cells (nMSCs) and/or their Secretomes/Exosomes from the US Patent Office

by secretome | May 23, 2023 | Investors, News

BALTIMORE–(BUSINESS WIRE)–NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and...